Evra patch, transdermal therapeutic system 3 pcs — Made in Belgium — Free Delivery

Brand: Janssen
Product Code: Evra
Availability: 5-10 Days

$34.58

Description

Product description

The patch - transdermal therapeutic system (TTS) "Evra®" is used for contraception in women.

The preparation is indicated for use in women of reproductive age. The safety and efficacy of the Evra® TTC patch have been established only for women aged 18 to 45 years.

The decision to prescribe Evra® should take into account the current risk factors for each woman, especially in relation to venous thromboembolism (VTE), taking into account the risk of venous thromboembolism (VTE) when using Evra® compared with other combined hormonal contraceptives (CHCs) .

Compound

1 patch with an area of 20 cm2 contains (active ingredients):

norelgestromin - 6.0 mg;

ethinylestradiol - 0.60 mg.

Each patch releases 203 micrograms of norelgestromin and 33.9 micrograms of ethinylestradiol within 24 hours.

Excipients: adhesive mixture of polyisobutylene and polybutene, lauryl lactate, crospovidone.

Contraindications

Combined hormonal contraceptives (CHCs) should not be used if one of the following conditions is present. If any of these conditions occurs when using the preparation "Evra®", its use should be stopped immediately.

Venous thromboembolism (VTE) or the risk of its development:

venous thromboembolism (with treatment with anticoagulants) or a history of VTE (deep vein thrombosis (DVT) or pulmonary embolism (PE));
hereditary or acquired tendency to venous thromboembolism, such as resistance to activated protein C (including factor V Leiden), deficiency of antithrombin III, protein C, protein S;
extensive surgery with prolonged immobilization;
increased risk of venous thromboembolism due to the presence of multiple risk factors.

Arterial thromboembolism (ATE) or the risk of its development:

arterial thromboembolism, including history (eg myocardial infarction), or prodromal stage of thrombosis (eg angina pectoris);
cerebrovascular diseases: acute cerebrovascular accident, history of stroke or prodromal stage of thrombosis (for example, transient ischemic attack);
hereditary or acquired tendency to arterial thrombosis, such as hyperhomocysteinemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
migraine with local neurological symptoms in history;
increased risk of arterial thromboembolism due to the presence of multiple risk factors or one of the following major risk factors:
diabetes mellitus with vascular symptoms;
severe arterial hypertension;
severe dyslipoproteinemia.

Hypersensitivity to the active ingredients of the preparationor to any of the excipients.

Confirmed or suspected breast carcinoma.

Endometrial cancer or other confirmed or suspected estrogen-dependent neoplasms.

Liver dysfunction due to acute or chronic hepatocellular disease.

Adenoma or carcinoma of the liver.

Undiagnosed genital bleeding.

Simultaneous use with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir.

Mode of application

To achieve the maximum contraceptive effect, a woman should use the Evra® patch (TTC), strictly following the instructions.

Only 1 patch (TTS) "Evra®" can be used at the same time.

Remove each used Evra® patch (TTS) and immediately replace it with a new one on the same day of the week - the “replacement day” - on the 8th and 15th days of the menstrual cycle. The replacement of the used patch can be carried out at any time of the “change day”. During the 4th week, from the 22nd day of the cycle, do not use the Evra® patch (TTS).

A new contraceptive cycle begins the next day after the end of the 4th week; the next patch (TTC) "Evra®" should be pasted, even if there was no withdrawal bleeding or it did not end.

Under no circumstances should the break in the use of the patch (TTS) "Evra®" exceed 7 days. If there is a break longer than 7 days, the woman may not be protected from pregnancy. In such cases, it is necessary to additionally use a barrier method of contraception for 7 days, since the risk of ovulation is growing every day, an increase in the recommended duration of the period free from the use of the Evra® patch (TTC). In the case of sexual intercourse during such a period, the likelihood of conception should be taken into account.

How to use

Plasters (TTS) "Evra®" should be applied to clean, dry, intact and healthy skin of the buttocks, abdomen, outer surface of the upper shoulder or upper body without hair, in areas where it will not come into contact with clothing that fits snugly against body. Plasters (TTS) "Evra®" should not be glued to the chest or skin areas with redness, irritation or cuts. To avoid possible irritation, each next Evra® patch (TTC) must be glued to a different area of the skin, this can be done within the same anatomical region.

The patch (TTC) "Evra®" must be pressed tightly so that its edges fit well to the skin.

To prevent a decrease in the adhesive properties of the patch (TTS) "Evra®" do not apply makeup, creams, lotions, powders and other local products on those areas of the skin where it is glued or will be glued.

The woman should inspect the transdermal patch daily to ensure that it is firmly adhered.

Patches (TTS) "Evra®" must not be cut, damaged or modified in any way, as this may compromise the effectiveness of contraception.

The used transdermal patch must be disposed of according to the instructions.

Application features

pregnant

Evra® patch is not indicated for use during pregnancy.

Also, the use of combined hormonal contraceptives in the postpartum period can adversely affect the quantity and quality of breast milk. Breastfeeding women should not use the patch (TTS) "Evra®" until the end of the period of breastfeeding.

After discontinuation of the preparation "Evra®" there may be a delay in fertilization.

Children

Plasters (TTS) "Evra®" are not recommended for children (under 18 years of age) due to insufficient data on safety and efficacy. It is not recommended to use the preparation "Evra®" before the onset of the first menstruation.

Drivers

Plasters (TTS) "Evra®" does not affect or slightly affects the reaction rate when driving vehicles or working with other mechanisms.

Overdose

In case of accidental use of large doses of oral contraceptives, no serious adverse reactions have been reported. An overdose may cause nausea or vomiting. Some women may experience vaginal bleeding. If an overdose is suspected, it is necessary to remove the Evra® patch (TTC) and carry out symptomatic therapy.

Side effects

The most common adverse reactions observed during clinical studies were headache, nausea and breast tenderness, which developed in approximately 21%, 16.6% and 15.9% of cases, respectively. Adverse reactions that may appear early in treatment but usually disappear after the first three cycles include spotting, breast engorgement, and nausea.

Storage conditions

Store in the original packaging at a temperature not exceeding 30°C, out of the reach of children. Do not store in refrigerator or freezer.

Shelf life - 2 years.

0 reviews

There are no reviews for this product.